Overview

Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to identify the maximum tolerated dose(s) (MTD) of neratinib in combination with temsirolimus in subjects with solid tumors. This study will also include a preliminary evaluation of efficacy, and assessment of pharmacokinetic (PK) parameters of the combination.
Phase:
Phase 1
Details
Lead Sponsor:
Puma Biotechnology, Inc.
Treatments:
Everolimus
Sirolimus